> top > docs > PubMed:26269629 > annotations

PubMed:26269629 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T5 4-23 D010300 denotes Parkinson's Disease
T6 4-23 D010300 denotes Parkinson's Disease
T9 35-43 SO:0000109 denotes Mutation
T10 44-49 PR:Q5S006 denotes LRRK2
T11 44-49 PR:000003033 denotes LRRK2
T12 44-49 PR:Q5S007 denotes LRRK2
T13 88-93 10090 denotes Mouse
T14 88-93 D051379 denotes Mouse
T15 94-105 UBERON:0002421 denotes Hippocampus
T16 94-105 UBERON:0001954 denotes Hippocampus
T17 94-105 UBERON:0002961 denotes Hippocampus
T22 119-138 D010300 denotes Parkinson's disease
T23 119-138 D010300 denotes Parkinson's disease
T26 155-172 D009069 denotes movement disorder
T27 155-172 D009069 denotes movement disorder
T32 202-210 3628 denotes dopamine
T28 202-210 CHEBI:59905 denotes dopamine
T29 202-210 CHEBI:18243 denotes dopamine
T30 202-210 D004298 denotes dopamine
T31 202-210 D004298 denotes dopamine
T33 223-232 GO:0009058 denotes formation
T34 308-313 UBERON:6110636 denotes brain
T35 308-313 UBERON:0000955 denotes brain
T36 490-496 GO:0007613 denotes memory
T37 523-527 SO:0000704 denotes gene
T39 532-539 6308 denotes leucine
T40 532-539 SO:0001437 denotes leucine
T38 532-539 CHEBI:15603 denotes leucine
T41 532-539 D007930 denotes leucine
T42 532-539 CHEBI:25017 denotes leucine
T43 532-539 D007930 denotes leucine
T44 545-551 SO:0001068 denotes repeat
T46 560-567 6308 denotes leucine
T47 560-567 SO:0001437 denotes leucine
T45 560-567 CHEBI:15603 denotes leucine
T48 560-567 D007930 denotes leucine
T49 560-567 CHEBI:25017 denotes leucine
T50 560-567 D007930 denotes leucine
T51 573-579 SO:0001068 denotes repeat
T52 590-595 PR:Q5S006 denotes LRRK2
T53 590-595 PR:000003033 denotes LRRK2
T54 590-595 PR:Q5S007 denotes LRRK2
T55 621-626 UBERON:6110636 denotes brain
T56 621-626 UBERON:0000955 denotes brain
T57 692-701 UBERON:0001950 denotes neocortex
T58 706-717 UBERON:0002421 denotes hippocampus
T59 706-717 UBERON:0001954 denotes hippocampus
T60 706-717 UBERON:0002961 denotes hippocampus
T61 738-743 PR:Q5S006 denotes LRRK2
T62 738-743 PR:000003033 denotes LRRK2
T63 738-743 PR:Q5S007 denotes LRRK2
T64 800-807 32644 denotes unknown
T65 822-853 SO:0000153 denotes bacterial artificial chromosome
T66 832-842 32630 denotes artificial
T67 843-853 GO:0005694 denotes chromosome
T69 854-864 SO:0000781 denotes transgenic
T70 854-870 D008822 denotes transgenic mouse
T73 881-886 PR:Q5S006 denotes LRRK2
T74 881-886 PR:000003033 denotes LRRK2
T75 881-886 PR:Q5S007 denotes LRRK2
T77 980-1011 GO:0098685 denotes Schaffer collateral-CA1 synapse
T79 1000-1003 Q99153 denotes CA1
T81 1000-1003 P54089 denotes CA1
T82 1000-1003 P54090 denotes CA1
T83 1000-1003 Q9IZU5 denotes CA1
T84 1000-1003 PR:B0BNN3 denotes CA1
T85 1000-1003 PR:000004912 denotes CA1
T86 1000-1003 PR:P00915 denotes CA1
T87 1000-1003 PR:P27140 denotes CA1
T88 1000-1003 P54087 denotes CA1
T89 1000-1003 PR:P13634 denotes CA1
T90 1000-1003 P20507 denotes CA1
T91 1000-1003 P54088 denotes CA1
T78 1000-1003 CVCL_B844 denotes CA1
T80 1000-1003 UBERON:0003881 denotes CA1
T93 1022-1033 UBERON:0002421 denotes hippocampus
T94 1022-1033 UBERON:0001954 denotes hippocampus
T95 1022-1033 UBERON:0002961 denotes hippocampus
T96 1066-1071 PR:Q5S006 denotes LRRK2
T97 1066-1071 PR:000003033 denotes LRRK2
T98 1066-1071 PR:Q5S007 denotes LRRK2
T99 1162-1182 GO:0060292 denotes long-term depression
T100 1167-1171 original_id denotes term
T101 1172-1182 UBERON:0004704 denotes depression
T102 1225-1233 SO:0000109 denotes mutation
T103 1297-1302 PR:Q5S006 denotes LRRK2
T104 1297-1302 PR:000003033 denotes LRRK2
T105 1297-1302 PR:Q5S007 denotes LRRK2
T106 1303-1318 GO:0016301 denotes kinase activity
T107 1351-1360 SO:0000817 denotes wild-type
T108 1361-1366 PR:Q5S006 denotes LRRK2
T109 1361-1366 PR:000003033 denotes LRRK2
T110 1361-1366 PR:Q5S007 denotes LRRK2
T111 1455-1463 SO:0000109 denotes mutation
T112 1513-1518 PR:Q5S006 denotes LRRK2
T113 1513-1518 PR:000003033 denotes LRRK2
T114 1513-1518 PR:Q5S007 denotes LRRK2
T115 1526-1537 UBERON:0002421 denotes hippocampus
T116 1526-1537 UBERON:0001954 denotes hippocampus
T117 1526-1537 UBERON:0002961 denotes hippocampus
T122 1610-1629 D010300 denotes Parkinson's disease
T123 1610-1629 D010300 denotes Parkinson's disease
T126 1727-1732 UBERON:6110636 denotes brain
T127 1727-1732 UBERON:0000955 denotes brain
T128 1783-1789 D014202 denotes tremor
T129 1783-1789 D014202 denotes tremor
T130 1919-1929 UBERON:0004704 denotes depression
T131 1934-1940 GO:0007613 denotes memory
T132 1934-1945 D008569 denotes memory loss
T133 1934-1945 D008569 denotes memory loss
T134 2074-2082 SO:0000109 denotes mutation
T136 2086-2093 6308 denotes leucine
T135 2086-2093 CHEBI:15603 denotes leucine
T138 2086-2093 D007930 denotes leucine
T139 2086-2093 CHEBI:25017 denotes leucine
T140 2086-2093 D007930 denotes leucine
T137 2086-2093 SO:0001437 denotes leucine
T141 2099-2105 SO:0001068 denotes repeat
T142 2122-2127 10090 denotes mouse
T143 2122-2127 D051379 denotes mouse
T144 2128-2139 UBERON:0002421 denotes hippocampus
T145 2128-2139 UBERON:0001954 denotes hippocampus
T146 2128-2139 UBERON:0002961 denotes hippocampus
T147 2152-2161 UBERON:0000955 denotes the brain
T150 2270-2288 D019954 denotes cognitive symptoms
T151 2270-2288 D019954 denotes cognitive symptoms
T152 2306-2314 SO:0000109 denotes mutation

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-106 DRI_Challenge denotes The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
T2 119-248 DRI_Challenge denotes Parkinson's disease (PD) is a major movement disorder characterized by the loss of dopamine neurons and formation of Lewy bodies.
T3 249-497 DRI_Challenge denotes Clinical and pathological evidence indicates that multiple brain regions are affected in PD in a spatiotemporal manner and are associated with a variety of motor and nonmotor symptoms, including disturbances in mood, executive function, and memory.
T4 498-808 DRI_Challenge denotes The common PD-associated gene for leucine-rich repeat kinase, leucine-rich repeat kinase 2 (LRRK2), is highly expressed in brain regions that are involved with nonmotor functions, including the neocortex and hippocampus, but whether mutant LRRK2 contributes to neuronal dysfunction in these regions is unknown.
T5 809-934 DRI_Outcome denotes Here, we use bacterial artificial chromosome transgenic mouse models of LRRK2 to explore potential nonmotor mechanisms of PD.
T6 935-1183 DRI_Outcome denotes Through electrophysiological analysis of the Schaffer collateral-CA1 synapse in dorsal hippocampus, we find that overexpression of LRRK2-G2019S increases basal synaptic efficiency through a postsynaptic mechanism, and disrupts long-term depression.
T7 1184-1319 DRI_Challenge denotes Furthermore, these effects of the G2019S mutation are age dependent and can be normalized by acute inhibition of LRRK2 kinase activity.
T8 1320-1464 DRI_Background denotes In contrast, overexpression of wild-type LRRK2 has no effect under the same conditions, suggesting a specific phenotype for the G2019S mutation.
T9 1465-1585 DRI_Challenge denotes These results identify a pathogenic function of LRRK2 in the hippocampus that may contribute to nonmotor symptoms of PD.
T10 1610-1824 DRI_Background denotes Parkinson's disease (PD) is among the most common neurological diseases and is best known for its adverse effects on brain regions that control motor function, resulting in tremor, rigidity, and gait abnormalities.
T11 1825-2014 DRI_Challenge denotes Less well appreciated are the psychiatric symptoms experienced by many PD patients, including depression and memory loss, which do not respond well to currently available treatments for PD.
T12 2015-2218 DRI_Outcome denotes Here, we describe functional effects of a common PD-linked mutation of leucine-rich repeat kinase 2 in the mouse hippocampus, an area of the brain that is responsible for encoding and retaining memories.
T13 2219-2403 DRI_Challenge denotes By providing a potential mechanism for some of the cognitive symptoms produced by this mutation, our findings may lead to novel approaches for the treatment of nonmotor symptoms of PD.

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 119-1585 UNLABELLED denotes Parkinson's disease (PD) is a major movement disorder characterized by the loss of dopamine neurons and formation of Lewy bodies. Clinical and pathological evidence indicates that multiple brain regions are affected in PD in a spatiotemporal manner and are associated with a variety of motor and nonmotor symptoms, including disturbances in mood, executive function, and memory. The common PD-associated gene for leucine-rich repeat kinase, leucine-rich repeat kinase 2 (LRRK2), is highly expressed in brain regions that are involved with nonmotor functions, including the neocortex and hippocampus, but whether mutant LRRK2 contributes to neuronal dysfunction in these regions is unknown. Here, we use bacterial artificial chromosome transgenic mouse models of LRRK2 to explore potential nonmotor mechanisms of PD. Through electrophysiological analysis of the Schaffer collateral-CA1 synapse in dorsal hippocampus, we find that overexpression of LRRK2-G2019S increases basal synaptic efficiency through a postsynaptic mechanism, and disrupts long-term depression. Furthermore, these effects of the G2019S mutation are age dependent and can be normalized by acute inhibition of LRRK2 kinase activity. In contrast, overexpression of wild-type LRRK2 has no effect under the same conditions, suggesting a specific phenotype for the G2019S mutation. These results identify a pathogenic function of LRRK2 in the hippocampus that may contribute to nonmotor symptoms of PD.
T2 1610-2403 UNASSIGNED denotes Parkinson's disease (PD) is among the most common neurological diseases and is best known for its adverse effects on brain regions that control motor function, resulting in tremor, rigidity, and gait abnormalities. Less well appreciated are the psychiatric symptoms experienced by many PD patients, including depression and memory loss, which do not respond well to currently available treatments for PD. Here, we describe functional effects of a common PD-linked mutation of leucine-rich repeat kinase 2 in the mouse hippocampus, an area of the brain that is responsible for encoding and retaining memories. By providing a potential mechanism for some of the cognitive symptoms produced by this mutation, our findings may lead to novel approaches for the treatment of nonmotor symptoms of PD.